JPRN-jRCT2080224078终止2 期
Early phase 2 clinical trial of E6011 in patients with active Crohn's disease
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •(1) Crohn's disease patients aged 18 or over and under 65 on the date of consent.
- •(2) Patients diagnosed on basis of clinical findings, endoscopic findings, etc. with small intestine-type, small and large intestine-type, or large intestine-type Crohn's disease at least 12 weeks before giving consent.
- •(3) Patients with a baseline disease severity ranging from moderate to severe. CDAI score between 220 and 450, and a PRO2 score between 14 and 34.
- •(4) Patients with a Simple Endoscopic Score for Crohn's Disease (SES-CD) between 7 and 15 in the screening period, with one or more ulcers (in SES-CD score, ulcer presence subscore >= 1 in any segment) assessed by colonoscopy and confirmed by a centralised review.
- •(5) Patients who received adrenocorticosteroids or immunomodulators in the past, but showed no therapeutic response (insufficient response) or the drugs were not tolerated (intolerance). Alternatively, patients who cannot taper oral adrenocorticosteroids (dependence). Alternatively, patients who showed no therapeutic response after administering one biologic (primary nonresponse), patients who initially showed therapeutic response but it lessened or disappeared afterwards (secondary nonresponse), or patients who did not tolerate the drug (intolerance).
排除标准
- •(1) Patients diagnosed with ulcerative colitis or indeterminate colitis.
- •(2) Patients diagnosed with gastric epithelial dysplasia.
- •(3) Patients who have an abscess or are suspected to have one.
- •(4) Patients with an artificial anus, ileo-anal pouch or fistula.
- •(5) Patients with symptomatic or high-grade gastrointestinal stenosis.
- •(6) Patients who, after undergoing small bowel resection, have been diagnosed with a short bowel syndrome, which makes maintaining caloric intake difficult.
- •(7) Patients who tested positive for C.difficile toxin test in the screening period.
- •(8) Patients who tested positive for HIV, HBsAg, anti-HBs, anti-HBc, HBV-DNA, anti-HCV, or anti-HTLV-1 in the screening period.
- •(9) Patients with positive or repeated indeterminate (inconclusive) results on the TB test.
- •(10) Patients with findings showing a history of tuberculosis on a chest X-ray test in the screening period.
- •(11) Patients with findings of neurological symptoms such as motor impairment, cognitive disorder, language disorder or dysphagia in the evaluations during the screening period.
- •(12) Patients with a WBC count of less than 3,000/micro-L or blood CD4-positive cell count under 200/micro-L in the screening period tests.
- •(13) Patients with a medical history of clinically significant vasculitis.
- •(14) Acute myocardial infarction, unstable angina pectoris, cerebral infarction, and symptomatic cerebral haemorrhage patients.
- •(15) Patients whose AST or ALT was more than twice the upper normal limit in the screening period tests or patients whose serum creatinine level exceeded 1.5 mg/dL in the screening period tests.
- •(16) Patients with a QTcF exceeding 450 ms repeatedly in standard 12-lead ECG tests in the screening period tests.
- •(17) Patients with a history of a malignant tumour, lymphoma, leukemia, or lymphoproliferative disorders.
- •(18) Patients with immunodeficiency or a history of HIV infection.
- •(19) Patients with a history of severe allergy
- •(20) Patients currently taking part in another clinical trial, or patients who were participating in another trial using an investigational drug or investigational medical device within 28 days prior to giving consent.
- •(21) Female patients of childbearing potential who had a positive result on the pregnancy test at screening or baseline, as well as lactating patients.
- •(22) Patients who were judged to be unsuitable for participation in this clinical trial by the Principal Investigator or Sub-investigator.
研究者
相似试验
进行中（未招募）
1 期
A research aimed study to test the efficacy and safety of a new medical product, called E6011, in treating Crohn’s disease, which is a type of inflammatory bowel diseaseActive Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-002109-70-HUEA Pharma Co., Ltd.40
进行中（未招募）
1 期
A research aimed study to test the efficacy and safety of a new medical product, called E6011, in treating Crohn’s disease, which is a type of inflammatory bowel diseaseActive Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-002109-70-CZEA Pharma Co., Ltd.40
未知
1 期
A Phase 1 Clinical Study of E6130 -Clinical Pharmacology Study in Healthy Adult Male SubjectsHealthy Adult SubjectsJPRN-jRCT2080223723EA Pharma Co., Ltd.44
已完成
2 期
A Study of E6011 in Participants With Active Crohn's DiseaseCrohn's DiseaseNCT03733314EA Pharma Co., Ltd.25
进行中（未招募）
1 期
A trial to investigate the use of Veregen ointment in the treatment of vulval intraepithelial neoplasia, a severe skin disorder that may lead to vulval cancer.Vulval intraepithelial neoplasia (VIN)MedDRA version: 16.1Level: LLTClassification code 10057313Term: Vulval intraepithelial neoplasia grade IIISystem Organ Class: 100000004864EUCTR2013-003107-19-GBniversity of Birmingham26